Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
企業コードAKYA
会社名Akoya Biosciences Inc
上場日Apr 16, 2021
最高経営責任者「CEO」Mr. Brian Mckelligon
従業員数205
証券種類Ordinary Share
決算期末Apr 16
本社所在地100 Campus Drive
都市MARLBOROUGH
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号01762
電話番号18558968401
ウェブサイトhttps://www.akoyabio.com/
企業コードAKYA
上場日Apr 16, 2021
最高経営責任者「CEO」Mr. Brian Mckelligon
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし